Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy of EMDR Versus CBT for Post-Traumatic Stress Disorder in Pakistan

24. September 2026 aktualisiert von: Dr. Anwar Khan, Khushal Khan Khattak Univeristy, Karak, Pakistan

Efficacy of Eye Movement Desensitization and Reprocessing Versus Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder and Comorbid Disorders in Pakistan: A Full-Fledged Randomized Controlled Trial

This randomized controlled trial compares Eye Movement Desensitization and Reprocessing (EMDR) therapy with Cognitive Behavioral Therapy (CBT) for the treatment of post-traumatic stress disorder (PTSD) in Pakistan. The study examines whether EMDR is at least as effective as CBT in reducing PTSD symptoms over time. It also assesses changes in symptoms of depression and anxiety that commonly occur alongside PTSD. Participants are randomly assigned to receive either EMDR or CBT, and their symptoms are assessed at different stages of treatment and follow-up.

Studienübersicht

Detaillierte Beschreibung

This study is a multi-center, single-blind, two-group randomized controlled trial designed to compare Eye Movement Desensitization and Reprocessing (EMDR) therapy with Cognitive Behavioral Therapy (CBT) for the treatment of post-traumatic stress disorder (PTSD) and associated symptoms of depression and anxiety.

The study is conducted in sequential phases. During the initial phase, the psychometric properties of the assessment measures are examined and treatment fidelity is evaluated to determine whether EMDR and CBT are delivered consistently and in accordance with their respective treatment protocols. The subsequent phase focuses on the comparative clinical effectiveness of EMDR and CBT.

Eligible participants with PTSD are randomly allocated to either the EMDR or CBT treatment condition using a covariate-adaptive stratified randomization procedure with a 1:1 allocation ratio. Treatment is delivered face-to-face by clinical psychologists trained in the respective psychotherapeutic approaches. The number of treatment sessions varies according to participants' clinical needs and symptom severity.

The primary objective is to examine whether EMDR is non-inferior to CBT in reducing PTSD symptoms. Additional objectives are to examine changes in PTSD symptoms over the course of treatment and follow-up, assess changes in associated depressive and anxiety symptoms, and explore the relationship between changes in PTSD symptoms and changes in these comorbid symptoms.

PTSD symptoms are assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Depressive symptoms are assessed using the Hamilton Depression Rating Scale (HDRS), and anxiety symptoms are assessed using the State-Trait Anxiety Inventory (STAI). Assessments are conducted at baseline, during treatment, at the end of treatment, and at follow-up.

Treatment fidelity is also evaluated by assessing therapists' adherence to the EMDR and CBT protocols and their competence in delivering the interventions.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

80

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Islamabad, Pakistan, 4400
        • Dr Farzana Bashir Clinic, Gulberg Green Office# G-67, Opal Sqaure, Islamabad (Wellness Clinic )
      • Peshawar, Pakistan, 25000
        • Paraplegic Center Peshawar
      • Peshawar, Pakistan, 25000
        • Psychiatry Unit & Rehabilitation Center, Lady Reading Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

15 Jahre bis 60 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Aged 15 to 60 years.
  • Confirmed diagnosis of post-traumatic stress disorder (PTSD), with PTSD identified as the primary clinical condition.
  • Associated symptoms of depression and anxiety at screening.
  • Able to participate in face-to-face psychotherapy and perform the basic eye and hand movements required for the treatment procedures.
  • Able to provide informed consent and communicate sufficiently to participate meaningfully in assessment and psychotherapy.

Exclusion Criteria:

  • Younger than 15 years or older than 60 years.
  • Significant limitations in eye or hand movement, or inability to perform the basic movements required for participation in the treatment procedures.
  • Prolonged unconsciousness or otherwise unable to maintain sufficient consciousness to participate meaningfully in assessment or psychotherapy.
  • Does not meet the screening criteria for PTSD, or PTSD is not the primary clinical condition.
  • Severe intellectual impairment that substantially limits the ability to understand, communicate, or participate in the assessment and psychotherapy procedures.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Eye Movement Desensitization and Reprocessing (EMDR) Therapy

Participants assigned to this arm received face-to-face Eye Movement Desensitization and Reprocessing (EMDR) therapy delivered by clinical psychologists trained in EMDR. Treatment followed an eight-stage EMDR protocol for PTSD, with culturally adapted procedures used where appropriate. The number of sessions varied according to symptom severity and clinical need, generally ranging from 6 to 14 sessions, typically delivered once per week. PTSD, depressive, and anxiety symptoms were assessed at baseline, during treatment, at the end of treatment, and at follow-up

Eye Movement Desensitization and Reprocessing (EMDR) therapy was delivered face-to-face by clinical psychologists trained and certified in EMDR. Treatment followed an eight-stage EMDR protocol for post-traumatic stress disorder (PTSD), incorporating culturally adapted procedures where appropriate for the Pakistani clinical context. Treatment included history-taking and treatment planning, preparation, assessment, desensitization using bilateral stimulation, installation of adaptive cognitions, body scan, closure, and reevaluation. The number of sessions was determined according to participants' symptom severity and clinical needs and generally ranged from 6 to 14 sessions, typically delivered once per week.

Aktiver Komparator: Cognitive Behavioral Therapy (CBT)

Participants assigned to this arm received face-to-face Cognitive Behavioral Therapy (CBT) delivered by clinical psychologists trained in CBT. Treatment followed a structured trauma-focused CBT protocol, with culturally adapted procedures used where appropriate. The number of sessions varied according to symptom severity and clinical need, generally ranging from 6 to 14 sessions, typically delivered once per week. PTSD, depressive, and anxiety symptoms were assessed at baseline, during treatment, at the end of treatment, and at follow-up.

Cognitive Behavioral Therapy (CBT) was delivered face-to-face by clinical psychologists trained and certified in CBT. Treatment followed a structured trauma-focused CBT protocol for post-traumatic stress disorder (PTSD), with culturally adapted procedures used where appropriate for the Pakistani clinical context. Treatment included assessment and engagement, psychoeducation, relaxation, affective modulation, cognitive coping and restructuring, trauma narrative work, exposure-based procedures, caregiver involvement where appropriate, and enhancement of safety. The number of sessions was determined according to participants' symptom severity and clinical needs and generally ranged from 6 to 14 sessions, typically delivered once per week.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Post-traumatic stress disorder symptoms
Zeitfenster: Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

PTSD symptom severity was assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). CAPS-5 scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in PTSD symptoms over time and to compare the EMDR and CBT treatment groups.

Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Depressive symptoms
Zeitfenster: Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HDRS). Scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in depressive symptoms over time in the EMDR and CBT treatment groups.

Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
Anxiety symptoms
Zeitfenster: Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Anxiety symptoms were assessed using the State-Trait Anxiety Inventory (STAI). Scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in anxiety symptoms over time in the EMDR and CBT treatment groups.

Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. Mai 2022

Primärer Abschluss (Tatsächlich)

28. Februar 2024

Studienabschluss (Tatsächlich)

1. März 2024

Studienanmeldedaten

Zuerst eingereicht

1. Februar 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. Mai 2024

Zuerst gepostet (Tatsächlich)

30. Mai 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

24. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data (IPD) will not be shared. The study involves sensitive mental health, trauma-related, and clinical information, and the consent and ethical framework for the study did not provide for public or external sharing of individual-level participant data. Aggregate study findings may be reported in publications and other research outputs.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren